Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Upgrades Immunocore Hldgs to Buy

Goldman Sachs analyst Rajan Sharma upgrades Immunocore Hldgs (NASDAQ:IMCR) from Neutral to Buy.

byBenzinga Newsdesk

December 16, 2022

1 minute read

Goldman Sachs analyst Rajan Sharma upgrades Immunocore Hldgs (NASDAQ:IMCR) from Neutral to Buy.

Wedbush Maintains Outperform on Academy Sports, Raises Price Target to $57

By Benzinga Newsdesk

Today, 10:04 AM

Wedbush analyst Seth Basham maintains Academy Sports (NASDAQ:ASO) with a Outperform and raises the price target from $50 to $57.

ASO

4 Reasons Why This Coupa Software Analyst Is Turning Very Bearish; How Company Is ‘Lacking Competitively’

By Priya Nigam

Today, 10:04 AM

Coupa Software Inc (NASDAQ: COUP) faces significant near-term challenges, due to macroeconomic pressures and execution issues, according to RBC Capital Markets.

COUP

News

White House Says It Is Not Aware Of Any Consideration Of Scaling Back Planned SPR Release

By Benzinga Newsdesk

Today, 10:04 AM

- Reuters

USO

Needham Maintains Buy on Paramount Global, Lowers Price Target to $23

By Benzinga Newsdesk

Today, 10:04 AM

Needham analyst Laura Martin maintains Paramount Global (NASDAQ:PARA) with a Buy and lowers the price target from $36 to $23.

PARA

Goldman Sachs Upgrades Immunocore Hldgs to Buy

Related Posts

Wedbush Maintains Outperform on Academy Sports, Raises Price Target to $57

4 Reasons Why This Coupa Software Analyst Is Turning Very Bearish; How Company Is ‘Lacking Competitively’

White House Says It Is Not Aware Of Any Consideration Of Scaling Back Planned SPR Release

Needham Maintains Buy on Paramount Global, Lowers Price Target to $23